Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan 15;14(1):511-517.
eCollection 2022.

Safety and efficacy of nimodipine combined with flunarizine in patients with angioneurotic headache

Affiliations

Safety and efficacy of nimodipine combined with flunarizine in patients with angioneurotic headache

Tao Zhang et al. Am J Transl Res. .

Abstract

Objective: To observe the role of nimodipine combined with flunarizine on angioneurotic headache.

Methods: Altogether 101 patients with angioneurotic headache were divided into the control group (CG, n=51) and the therapy group (TG, n=50). Patients in the CG were given nimodipine, while patients in the TG were given flunarizine on the basis of nimodipine. The clinical efficacy and adverse reactions of patients were observed.

Results: After treatment, the Visual analog scale (VAS) scores of the TG were markedly lower than those in the CG, and the number of attacks and headache duration of patients in the TG were also markedly reduced. Observation of the clinical efficacy showed that the effective rate of the TG was markedly higher than that of the CG, but no additional adverse reactions were found. In addition, after treatment, the cerebral hemodynamics and quality of life of patients were improved.

Conclusion: Nimodipine combined with flunarizine can better promote the recovery of patients with angioneurotic headache and improve their quality of life.

Keywords: Angioneurotic headache; flunarizine; nimodipine.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

Figure 1
Figure 1
Comparison of VAS scores between two groups. After treatment, the VAS score (A) of patients in the control group and treatment group decreased significantly, and the frequency (B) and duration (C) of headache were shortened significantly. The VAS scores of patients in the treatment group were significantly lower than those in the control group, and the frequency and duration of headache attacks were significantly shorter than those in the control group. Note: *indicates P<0.05.
Figure 2
Figure 2
Comparison of arterial blood flow velocity between two groups before and after treatment. After treatment, ACA (A), MCA (B), PCA (C), VA (D) and BA (E) of patients in the CG and the TG decreased markedly, while those in TG decreased most markedly. Note: *indicates P<0.05.
Figure 3
Figure 3
Changes of quality of life before and after treatment in two groups. After treatment, the scores of general health, body pain, physiological function, mental health and emotional function of the patients in the two groups were markedly improved, and the scores in the TG were most markedly improved. Note: *indicates P<0.05.

Similar articles

Cited by

References

    1. Diener HC, Dodick D, Evers S, Holle D, Jensen RH, Lipton RB, Porreca F, Silberstein S, Schwedt T. Pathophysiology, prevention, and treatment of medication overuse headache. Lancet Neurol. 2019;18:891–902. - PubMed
    1. Burch RC, Buse DC, Lipton RB. Migraine: epidemiology, burden, and comorbidity. Neurol Clin. 2019;37:631–649. - PubMed
    1. Haanes KA, Edvinsson L. Pathophysiological mechanisms in migraine and the identification of new therapeutic targets. CNS Drugs. 2019;33:525–537. - PubMed
    1. Albers L, Kries RV, Straube A, Heinen F, Landgraf MN, Obermeier V, Ruscheweyh R. Age- and sex-specific first health care use for migraine in 2016 in children and adolescents from prospectively collected health insurance data in Germany. Cephalalgia. 2019;39:1156–1163. - PubMed
    1. Mancini AJ, Glassman RD, Chang YM, Burstein R, Ashina S. Headache in petrous apicitis: a case report of chronic migraine-like headache due to peripheral pathology. Headache. 2019;59:1821–1826. - PMC - PubMed

LinkOut - more resources